Latest Breaking News On - Catalyst pharmaceuticals inc - Page 3 : comparemela.com

Summit Global Investments Lowers Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Summit Global Investments Lowers Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
America
Brian-elsbernd
Sherbrooke-park-advisers
Financial-services-group-inc
Cantor-fitzgerald
News-ratings-for-catalyst-pharmaceuticals-daily
Catalyst-pharmaceuticals-stock-performance
Nisa-investment-advisors
Parkside-financial-bank
Insider-activity-at-catalyst-pharmaceuticals
Securities-exchange-commission

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of "Buy" by Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of "Buy" by Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
America
Davids-tierney
Catalyst-pharmaceuticals-inc
News-ratings-for-catalyst-pharmaceuticals-daily
Parkside-financial-bank
Sherbrooke-park-advisers
Catalyst-pharmaceuticals-company-profile
Catalyst-pharmaceuticals
Tower-research-capital
Catalyst-pharmaceuticals-price-performance

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $26.43 Average Price Target from Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $26.43 Average Price Target from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
America
Davids-tierney
Catalyst-pharmaceuticals-inc
News-ratings-for-catalyst-pharmaceuticals-daily
Parkside-financial-bank
Sherbrooke-park-advisers
Catalyst-pharmaceuticals-company-profile
Catalyst-pharmaceuticals
Tower-research-capital
Catalyst-pharmaceuticals-stock-performance

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating

Italy
United-states
Highbridge
Somerset
United-kingdom
Spain
Pratteln
Switzerland-general
Switzerland
France
Austria
China

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Santhera Pharmaceuticals Holding AG: Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

China
Austria
France
United-kingdom
Germany
Spain
Pratteln
Switzerland-general
Switzerland
Highbridge
Somerset
United-states